PharmaForm Announces Manufacturing Agreement
PharmaForm recently announced that Corcept Therapeutics Inc. has chosen them as their primary commercial manufacturer for their newly approved drug product, Korlym. The US FDA approved Corcept’s Korlym in February 2012 for patients with endogenous Cushing’s syndrome. PharmaForm has worked with Corcept for several years as a contract provider for services in the development, optimization, and validation of the manufacturing process for Corcept’s Korlym.
PharmaForm, a wholly owned subsidiary of Akela Pharma, Inc., is a leading specialty contract manufacturer for preclinical, clinical, and commercial products. PharmaForm specializes in the area of pharmaceutical dosage form development, controlled-release, and bioavailability-enhancement technologies, such as hot-melt extrusion, spray-drying, fluid bed processing, and liquid-filled capsules.
PharmaForm’s expertise along with its ability to handle certain class potent compounds places PharmaForm as a leader in the field of specialty pharmaceutical dosage formulation and GMP manufacturing. Through its diverse offerings, PharmaForm’s solutions help pharmaceutical and biotechnology clients reach their drug development targets, reduce development costs, and accelerate time-to-market for their products. For more information, visit www.pharmaform.com.
Total Page Views: 1938
